Vaccinex Statistics
Total Valuation
Vaccinex has a market cap or net worth of $8.42 million. The enterprise value is $8.94 million.
Important Dates
The next estimated earnings date is Friday, November 15, 2024, before market open.
| Earnings Date | Nov 15, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Vaccinex has 2.60 million shares outstanding. The number of shares has increased by 373.03% in one year.
| Shares Outstanding | 2.60M |
| Shares Change (YoY) | +373.03% |
| Shares Change (QoQ) | +36.94% |
| Owned by Insiders (%) | 0.41% |
| Owned by Institutions (%) | 13.34% |
| Float | 1.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.27 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 25.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.42
| Current Ratio | 0.42 |
| Quick Ratio | 0.24 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -495.64% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $8,900 |
| Profits Per Employee | -$443,925 |
| Employee Count | 40 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -75.11% in the last 52 weeks. The beta is 0.98, so Vaccinex's price volatility has been similar to the market average.
| Beta (5Y) | 0.98 |
| 52-Week Price Change | -75.11% |
| 50-Day Moving Average | 3.88 |
| 200-Day Moving Average | 6.12 |
| Relative Strength Index (RSI) | 49.94 |
| Average Volume (20 Days) | 192,466 |
Short Selling Information
The latest short interest is 34,501, so 1.33% of the outstanding shares have been sold short.
| Short Interest | 34,501 |
| Short Previous Month | 50,494 |
| Short % of Shares Out | 1.33% |
| Short % of Float | 2.62% |
| Short Ratio (days to cover) | 0.41 |
Income Statement
In the last 12 months, Vaccinex had revenue of $356,000 and -$17.76 million in losses. Loss per share was -$15.88.
| Revenue | 356,000 |
| Gross Profit | -14.60M |
| Operating Income | -21.62M |
| Pretax Income | -19.19M |
| Net Income | -17.76M |
| EBITDA | -21.51M |
| EBIT | -21.62M |
| Loss Per Share | -$15.88 |
Full Income StatementBalance Sheet
The company has $233,000 in cash and $122,000 in debt, giving a net cash position of $111,000 or $0.04 per share.
| Cash & Cash Equivalents | 233,000 |
| Total Debt | 122,000 |
| Net Cash | 111,000 |
| Net Cash Per Share | $0.04 |
| Equity (Book Value) | -2.86M |
| Book Value Per Share | -2.68 |
| Working Capital | -3.03M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$15.73 million and capital expenditures -$32,000, giving a free cash flow of -$15.77 million.
| Operating Cash Flow | -15.73M |
| Capital Expenditures | -32,000 |
| Free Cash Flow | -15.77M |
| FCF Per Share | -$6.06 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -6,072.47% |
| Pretax Margin | -4,987.92% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -13,583.87% |